ab-201
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2023 (NCT05678205)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, passive
ERBB2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06341647 | Phase 1 | Oct 31, 2024 | Green Cross Corporation |
| NCT05678205 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2023 | Artiva Biotherapeutics, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Artiva Biotherapeutics, Inc. | For profit | 1 | 1 | 1 | 2023 |
| Green Cross Corporation | For profit | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1